European Journal of Cancer
Volume 47, Issue 17 , Pages 2537-2545 , November 2011

Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer

  • Hyo Sook Han

      Affiliations

    • Department of Women’s Oncology, Breast Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    • ,
  • Isildinha M. Reis

      Affiliations

    • Department of Epidemiology and Public Health, Division of Biostatistics, University of Miami Miller School of Medicine, Miami, FL, USA
    • Biostatistics and Bioinformatics Core, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
    • ,
  • Wei Zhao

      Affiliations

    • Biostatistics and Bioinformatics Core, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
    • ,
  • Katsumasa Kuroi

      Affiliations

    • Department of Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan
    • ,
  • Masakazu Toi

      Affiliations

    • Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    • ,
  • Eiji Suzuki

      Affiliations

    • Department of Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan
    • ,
  • Rachel Syme

      Affiliations

    • Alberta Health Services, Cancer Care, Tom Baker Cancer Centre, Department of Oncology, University of Calgary, Alberta, Canada
    • ,
  • Louis Chow

      Affiliations

    • Organisation for Oncology and Translational Research, Hong Kong
    • Clinical Trials Centre, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
    • ,
  • Adrian Y.S. Yip

      Affiliations

    • Organisation for Oncology and Translational Research, Hong Kong
    • ,
  • Stefan Glück

      Affiliations

    • Department of Internal Medicine, Division of Hematology and Oncology, Sylvester Comprehensive Cancer Center, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA
    • Corresponding Author InformationCorresponding author:

References 

  1. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163(1):49–56
  2. Woodward WA, Huang EH, McNeese MD, et al. African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer; 2006.
  3. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. Jama. 2005;294(14):1765–1772
  4. Meng L, Maskarinec G, Lee J. Ethnicity and conditional breast cancer survival in Hawaii. J Clin Epidemiol. 1997;50(11):1289–1296
  5. Meng L, Maskarinec G, Wilkens L. Ethnic differences and factors related to breast cancer survival in Hawaii. Int J Epidemiol. 1997;26(6):1151–1158
  6. Citron ML. Dose density in adjuvant chemotherapy for breast cancer. Cancer Invest. 2004;22(4):555–568
  7. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20years of follow-up. N Engl J Med. 1995;332(14):901–906
  8. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330(18):1253–1259
  9. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205–1211
  10. Ma B, Yeo W, Hui P, Ho WM, Johnson PJ. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer – a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol. 2002;62(2):185–189
  11. Toi M, Nakamura S, Kuroi K, et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat. 2008;110(3):531–539
  12. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664–5671
  13. Dignam JJ. Differences in breast cancer prognosis among African–American and Caucasian women. CA Cancer J Clin. 2000;50(1):50–64
  14. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97(6):439–448
  15. Yen-Revollo JL, Auman JT, McLeod HL. Race does not explain genetic heterogeneity in pharmacogenomic pathways. Pharmacogenomics. 2008;9(11):1639–1645
  16. Colleoni M, Li S, Gelber RD, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet. 2005;366(9491):1108–1110
  17. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165(11):1267–1273
  18. Field KM, Kosmider S, Jefford M. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract. 2008;4:108–113
  19. Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007;25(30):4707–4713
  20. Lee L, Cheung WY, Atkinson E, Krzyzanowska MK. Impact of comorbidity on chemotherapy use and outcomes in sold tumor: a systemic review. J Clin Oncol. 2011;29(1):106–117

PII: S0959-8049(11)00431-X

doi: 10.1016/j.ejca.2011.06.027

European Journal of Cancer
Volume 47, Issue 17 , Pages 2537-2545 , November 2011

Article Tools

* Image Usage & Resolution